Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia
Yuh-Ying Yeh(The Ohio State University), Amy J. Johnson(Ouranos)
Cited by 45
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890
A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases.
|Journal of Clinical Oncology|2012|65
The regulation of tumor‐suppressive microRNA, miR‐126, in chronic lymphocytic leukemia
|Cancer Medicine|2017|16